0.5271 USD
-0.01 (-0.96%)
0.5307 USD
+0 (+0.68%)
We assign a fundamental rating of 2 out of 10 to MREO. MREO was compared to 525 industry peers in the Biotechnology industry. The financial health of MREO is average, but there are quite some concerns on its profitability. MREO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- MREO had negative earnings in the past year.
- MREO had a negative operating cash flow in the past year.
- MREO had negative earnings in 4 of the past 5 years.
- In the past 5 years MREO always reported negative operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of -77.77%, MREO is doing worse than 65.52% of the companies in the same industry.
- With a Return On Equity value of -89.46%, MREO perfoms like the industry average, outperforming 48.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -77.77% | ||
| ROE | -89.46% | ||
| ROIC | N/A |
ROA(3y)-46.82%
ROA(5y)-74.73%
ROE(3y)-61.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for MREO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- MREO does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, MREO has more shares outstanding
- Compared to 5 years ago, MREO has more shares outstanding
- Compared to 1 year ago, MREO has a worse debt to assets ratio.
2.2 Solvency
- MREO has an Altman-Z score of -7.54. This is a bad value and indicates that MREO is not financially healthy and even has some risk of bankruptcy.
- MREO has a Altman-Z score of -7.54. This is in the lower half of the industry: MREO underperforms 66.67% of its industry peers.
- There is no outstanding debt for MREO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.54 |
ROIC/WACCN/A
WACC9.09%
2.3 Liquidity
- MREO has a Current Ratio of 8.71. This indicates that MREO is financially healthy and has no problem in meeting its short term obligations.
- MREO has a better Current ratio (8.71) than 77.33% of its industry peers.
- A Quick Ratio of 8.71 indicates that MREO has no problem at all paying its short term obligations.
- The Quick ratio of MREO (8.71) is better than 77.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.71 | ||
| Quick Ratio | 8.71 |
3. Growth
3.1 Past
- MREO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.56%, which is quite impressive.
- The Revenue for MREO has decreased by -95.00% in the past year. This is quite bad
EPS 1Y (TTM)36.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90%
Revenue 1Y (TTM)-95%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 4.03% on average over the next years.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3.75%
EPS Next 2Y19.32%
EPS Next 3Y9.37%
EPS Next 5Y4.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for MREO. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MREO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.32%
EPS Next 3Y9.37%
5. Dividend
5.1 Amount
- MREO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MEREO BIOPHARMA GROUP PL-ADR / MREO FAQ
What is the ChartMill fundamental rating of MEREO BIOPHARMA GROUP PL-ADR (MREO) stock?
ChartMill assigns a fundamental rating of 2 / 10 to MREO.
Can you provide the valuation status for MEREO BIOPHARMA GROUP PL-ADR?
ChartMill assigns a valuation rating of 0 / 10 to MEREO BIOPHARMA GROUP PL-ADR (MREO). This can be considered as Overvalued.
Can you provide the profitability details for MEREO BIOPHARMA GROUP PL-ADR?
MEREO BIOPHARMA GROUP PL-ADR (MREO) has a profitability rating of 0 / 10.
What is the financial health of MEREO BIOPHARMA GROUP PL-ADR (MREO) stock?
The financial health rating of MEREO BIOPHARMA GROUP PL-ADR (MREO) is 6 / 10.